These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12138343)

  • 21. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma--associated herpesvirus infection in patients with and without Kaposi sarcoma.
    Gill J; Bourboulia D; Wilkinson J; Hayes P; Cope A; Marcelin AG; Calvez V; Gotch F; Boshoff C; Gazzard B
    J Acquir Immune Defic Syndr; 2002 Dec; 31(4):384-90. PubMed ID: 12447008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recommendations for treating life-threatening Kaposi sarcoma during pregnancy in HIV-positive women in low income countries.
    Bacha JM; El-Mallawany NK; Slone JS; Wilkinson JP; Mehta PS; Campbell LR
    Int J STD AIDS; 2020 Jul; 31(8):724-734. PubMed ID: 32493141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
    Martín-Carbonero L; Palacios R; Valencia E; Saballs P; Sirera G; Santos I; Baldobí F; Alegre M; Goyenechea A; Pedreira J; González del Castillo J; Martínez-Lacasa J; Ocampo A; Alsina M; Santos J; Podzamczer D; González-Lahoz J;
    Clin Infect Dis; 2008 Aug; 47(3):410-7. PubMed ID: 18582203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma.
    Tam HK; Zhang ZF; Jacobson LP; Margolick JB; Chmiel JS; Rinaldo C; Detels R
    Int J Cancer; 2002 Apr; 98(6):916-22. PubMed ID: 11948473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II study of liposomal doxorubicin in the treatment of HIV-related Kaposi's sarcoma.
    Newell M; Milliken S; Goldstein D; Lewis C; Boyle M; Dolan G; Ryan S; Cooper DA
    Aust N Z J Med; 1998 Dec; 28(6):777-83. PubMed ID: 9972406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcomes of HIV-infected patients with Kaposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda.
    Asiimwe F; Moore D; Were W; Nakityo R; Campbell J; Barasa A; Mermin J; Kaharuza F
    HIV Med; 2012 Mar; 13(3):166-71. PubMed ID: 22112164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. P-glycoprotein expression in HTLV-III cells after treatment with HIV-1 protease inhibitors.
    Sánchez Mdel C; López P; Vélez R; Yamamura Y
    Ethn Dis; 2008; 18(2 Suppl 2):S2-60-4. PubMed ID: 18646322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression.
    Ford J; Meaden ER; Hoggard PG; Dalton M; Newton P; Williams I; Khoo SH; Back DJ
    J Antimicrob Chemother; 2003 Sep; 52(3):354-8. PubMed ID: 12917239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced human herpesvirus-8 oropharyngeal shedding associated with protease inhibitor-based antiretroviral therapy.
    Gantt S; Cattamanchi A; Krantz E; Magaret A; Selke S; Kuntz SR; Huang ML; Corey L; Wald A; Casper C
    J Clin Virol; 2014 Jun; 60(2):127-32. PubMed ID: 24698158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma.
    Toffoli G; Corona G; Cattarossi G; Boiocchi M; Di Gennaro G; Tirelli U; Vaccher E
    Ann Oncol; 2004 Dec; 15(12):1805-9. PubMed ID: 15550586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of Kaposi's sarcoma in resource-limited settings in the era of HAART.
    Lynen L; Zolfo M; Huyst V; Louis F; Barnardt P; Van de Velde A; De Schacht C; Colebunders R
    AIDS Rev; 2005; 7(1):13-21. PubMed ID: 15875657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma.
    Fumagalli L; Zucchetti M; Parisi I; Viganò MG; Zecca B; Careddu A; D'Incalci M; Lazzarin A
    Cancer Chemother Pharmacol; 2000; 45(6):495-501. PubMed ID: 10854138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression levels of P-glycoprotein in peripheral blood CD8+ T lymphocytes from HIV-1-infected patients on antiretroviral therapy.
    Zhang JC; Xie F; Yu XH; Deng ZY; Wang Y; Liang P; Sun L; Zhang FX
    Int J Mol Med; 2014 Feb; 33(2):431-40. PubMed ID: 24337436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome.
    Cattelan AM; Calabrò ML; Gasperini P; Aversa SM; Zanchetta M; Meneghetti F; De Rossi A; Chieco-Bianchi L
    J Natl Cancer Inst Monogr; 2001; (28):44-9. PubMed ID: 11158206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implications of T-cell P-glycoprotein activity during HIV-1 infection and its therapy.
    Hulgan T; Donahue JP; Hawkins C; Unutmaz D; D'Aquila RT; Raffanti S; Nicotera F; Rebeiro P; Erdem H; Rueff M; Haas DW
    J Acquir Immune Defic Syndr; 2003 Oct; 34(2):119-26. PubMed ID: 14526200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study.
    Krown SE; Roy D; Lee JY; Dezube BJ; Reid EG; Venkataramanan R; Han K; Cesarman E; Dittmer DP
    J Acquir Immune Defic Syndr; 2012 Apr; 59(5):447-54. PubMed ID: 22067664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro.
    Chandler B; Almond L; Ford J; Owen A; Hoggard P; Khoo S; Back D
    J Acquir Immune Defic Syndr; 2003 Aug; 33(5):551-6. PubMed ID: 12902797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma.
    Northfelt DW; Martin FJ; Working P; Volberding PA; Russell J; Newman M; Amantea MA; Kaplan LD
    J Clin Pharmacol; 1996 Jan; 36(1):55-63. PubMed ID: 8932544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kaposi's sarcoma: Good outcome with doxorubicin, bleomycin and vincristine sulphate (ABV) chemotherapy and highly active antiretroviral therapy.
    Hesseling PB; Katayi E; Wharin P; Bardin R; Kouya F; Palmer D; Glenn M; Kruger M
    S Afr Med J; 2017 Oct; 107(11):952-953. PubMed ID: 29262935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodéficience humaine.
    Dupont C; Vasseur E; Beauchet A; Aegerter P; Berthé H; de Truchis P; Zucman D; Rouveix E; Saiag P
    AIDS; 2000 May; 14(8):987-93. PubMed ID: 10853980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.